Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: PDT, PLW

Avirmax Inc. Announces Issuance of U.S. Patent Covering Catalysis Deactivated Angiotensin-Converting Enzyme 2 (ACE2) Variants for Treatment of Beta Group SARS-COV Viral Infection

HAYWARD, Calif., Oct. 7, 2022 /PRNewswire/ -- Avirmax Inc.(www.avirmax.com), a company focused on delivering protein therapeutics via recombinant adeno-associated viral (rAAV) vectors announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,453,869, which is directed to the composition and methods related to the use and administration of catalysis deactivated angiotensin-converting enzyme 2 (ACE2) for preventing SARS-COV-1 and SARS-COV-2 infection.

Novel Decoy Proteins Blocking COVID-19 Variants 
Patent Summary

Human ACE2 has been confirmed as a specific receptor for several ? group coronaviruses including severe respiratory syndrome (SARS) coronavirus (SARS-CoV-1), a low pathogenic coronavirus of HCoV-NL63, a member in ?-coronavirus group and SARS-CoV-2, the causative agent of COVID-19. The patent covers the extracellular domain (ECD) polypeptide of ACE2 with one or more mutations in the enzyme catalytic center that cause the loss of ACE2 catalytic activity (herein referred as ACE2-vECD) and enhance the binding affinity to the SARS-CoV1 and SARS-COV-2 S1 spike proteins. The ACE2-vECD fused to the Fc fragment of human IgG1 (ACE2-vECD-Fc1) can function as a common blocking reagent, similar to neutralization antibodies, preventing COVID-19 variants or SARS-COV1 to enter host cells and the viral replication cycle. The rAAV mediated expression of the catalysis deactivated ACE2 in nasal/olfactory epithelium therefore acts as a decoy receptor for SARS-COV blocking infection of epithelial cells and the following viral replication.

About Avirmax Inc:

Avirmax, Inc., based in the San Francisco Bay Area, is dedicated to the innovation, development, and manufacture of adeno-associated virus (AAV) vector mediated biotherapeutics using its proprietary protein therapeutics and Bac-to-AAV technologies.

Avirmax's AAV Innovation Platform, a robust streamlined assembly line of novel AAV vector discovery and development, enables us to become a powerhouse of rAAV therapeutics due to its highly transducible AAV vectors with high titers at production and enhanced expression of gene of interest (GOI) in target cells. Our ultimate goal is to deliver patients with effective, safe, long-acting AAV-mediated biotherapeutics in the most affordable and accessible manner possible. (For more information, please visit www.avirmax.com.)

For more information, please contact
June Song
Executive Administration
Email: [email protected]
Tel: +1-510-641-0201

SOURCE Avirmax

These press releases may also interest you

at 20:30
The "Supercapacitors: Technology Developments and Global Markets" report has been added to  ResearchAndMarkets.com's offering. The report covers the market for supercapacitors with regard to the end-user base across different regions. It also...

at 20:25
Mannatech, Incorporated ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the...

at 20:15
The "Regenerative Medicines: Bone and Joint Applications" report has been added to  ResearchAndMarkets.com's offering. The global market for regenerative medicine for bone and joint applications was valued at $9.6 billion in 2022. By technology, this...

at 19:30
The "Scrubber System Global Market Report 2023" report has been added to  ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to assess the market.The global...

at 19:15
The "Shore Power Market Share, Size, Trends, Industry Analysis Report, By Installation Type , By Connection, By Component, By Power Rating, By Region, Segment Forecast, 2023- 2032" report has been added to  ResearchAndMarkets.com's offering. The...

at 19:00
The "Vehicle Analytics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)" report has been added to  ResearchAndMarkets.com's offering. The vehicle analytics market is expected to register a CAGR of 24.3% during the forecast period. ...

News published on and distributed by: